Longeveron LGVN 深 沪

Longeveron Announces Engagement of Lucid Capital Markets

Longeveron Inc. has retained Lucid Capital Markets as its financial advisor to explore potential strategic opportunities, including a business combination. The company specializes in developing regenerative medicines, with its lead product laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell therapy, receiving multiple FDA designations. Forward-looking statements are subject to risks and uncertainties that could impact future outcomes.

10-28 13:15

Longeveron Highlights Positive HLHS Trial Safety Findings

Longeveron ( ($LGVN) ) has provided an announcement. On October 26, 2026, Longe...

10-27 05:19

Longeveron Announces Its ELPIS II Study Of Laromestrocel Failed To Meet Primary Efficacy Endpoint Of Change From Baseline In Right Ventricular Ejection Fraction To Treat Infants With Hypoplastic Left Heart Syndrome

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced updated results from ELPIS II following planned additional analysis conducted by the Company and the National ...

10-26 21:18

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Inc. reported updated results from its ELPIS II Phase 2b trial evaluating laromestrocel in infants with hypoplastic left heart syndrome (HLHS). While the trial did not meet the primary endpoint of improving right ventricular ejection fraction (RVEF) at 12 months, a key secondary endpoint, major adverse cardiac events (MACE), showed statistical significance with 8 events in the standard of care arm versus 1 in the laromestrocel group (P...

10-26 13:15

Longeveron to Participate in Three Longevity/Aging Investment Conferences

Longeveron Inc. will participate in three upcoming longevity-related investment conferences. The company has published new analysis from a Phase 2a clinical trial showing that laromestrocel may reduce neuroinflammation in Alzheimer's disease, a key driver of disease progression. Key findings include inhibition of neuroinflammation in core brain regions, correlation with reduced brain atrophy and improved cognition, lower synaptic loss markers, an...

09-30 20:05

Longeveron (LGVN) Shares Slide 59% After Hours: Here's Why

Longeveron Inc (NASDAQ:LGVN) shares fell 59.58% to $2.70 in after-hours trading Wednesday after the company announced topline results from its Phase 2b ELPIS II clinical trial evaluating laromestrocel as a potential treatment for hypoplastic left heart syndrome. Longeveron is a clinical-stage biotec...

09-17 13:59

Longeveron Announces Phase 2b ELPIS II Trial Of Laromestrocel In Hypoplastic Left Heart Syndrome Misses Primary Efficacy Endpoint; Initiates Cost-Optimization Measures To Maximize Shareholder Value

The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a pot...

09-17 05:28

Longeveron Regains Nasdaq Compliance With Minimum Bid Price

The latest update is out from Longeveron ( ($LGVN) ). Longeveron Inc. disclosed...

09-15 04:27

Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference

09-03 13:15

Dick's Sporting Goods, Intuit And 3 Stocks To Watch Heading Into Tuesday

With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Dick’s Sporting Goods Inc. (NYSE:DKS) to post quarterly earnings of $3.77 per share on revenue of $5.65 billion before the opening bell, according ...

08-25 16:02